Romidepsin
Orphan Drug Cold Chain RequiredFDA Approved
Description
Romidepsin is a histone deacetylase (HDAC) inhibitor. It is approved for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
Indications & Therapeutic Use
Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Mantle cell lymphoma
Linked Diseases:
mantle cell lymphoma
C85.7D020522
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Romidepsin
| Generic Name | Romidepsin |
| Brands | 1 brand available |
| Active Ingredient | Romidepsin |
| Drug Class | Cutaneous T-cell lymphoma |
| Manufacturer | Celgene |
| Dosage Forms | IV infusion, 10mg/vial |
| Medical Code | L01XX41 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00078932 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes